MIGRAINE sufferers have been left devastated after being denied a ground-breaking drug on the NHS.
In draft guidance, watchdog the National Institute for Health and Care Excellence said it was promising but ruled that it is was not cost-effective. It also said there was not enough proof it was better than current treatment Botox.
Erenumab — developed by Dr Peter Goadsby, Professor of Neurology at King’s College London — costs around £5,000 a year, though the NHS would get it at a discount.
Experts estimate the drug would have helped 100,000 chronic cases. Wendy Thomas, of The Migraine Trust, said: “This is devastating for people whose lives are blighted. After proving effective to many, it is not accessible.”
The monthly self-administered jab works by blocking pain signals that trigger the crippling headaches.
Dr David Bloomfield, head of the National Migraine Centre, said: “We are disappointed.”
- GRANDAD Barrington Simner, 72, is the first Brit migraine sufferer cured with “zaps” from a device that delivers single pulse Transcranial Magnetic Stimulation at Guy’s and St Thomas’ Hospital, South London.